Skip to main content
SpringerLink
Log in

Wirksamkeit von Lanreotid bei metastasiertem neuroendokrinen Tumor des Gastrointestinaltrakts

Efficacy of lanreotide in metastatic neuroendocrine tumors of the gastrointestinal tract

  • Journal Club
  • Published:
Der Gastroenterologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Yao JC, Hassan M, Phan A et al (2008) One hundred years after „carcinoid“: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26: 3063–3072

    Article  PubMed  Google Scholar 

  2. Van der Zwan JM, Trama A, Otter R et al (2013) Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer 49: 2565–2578

    Article  Google Scholar 

  3. Susini C, Buscail L (2006) Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 17: 1733–1742

    Article  CAS  PubMed  Google Scholar 

  4. Toumpanakis C, Caplin ME (2013) Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol 40: 56–68

    Article  CAS  PubMed  Google Scholar 

  5. Rinke A, Müller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27: 4656–4663

    Article  CAS  PubMed  Google Scholar 

  6. Pavel M, Baudin E, Couvelard A et al (2012) ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95: 157–176

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

F. Schmitz gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Gastroenterologie und Onkologie, HELIOS Klinikum Hildesheim GmbH, Senator-Braun-Allee 33, 31135, Hildesheim, Deutschland

    F. Schmitz

Authors
  1. F. Schmitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Schmitz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schmitz, F. Wirksamkeit von Lanreotid bei metastasiertem neuroendokrinen Tumor des Gastrointestinaltrakts. Gastroenterologe 9, 470–472 (2014). https://doi.org/10.1007/s11377-014-0935-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11377-014-0935-y

Search

Navigation